MKI67 and adrenal cortex carcinoma: Although current guidelines recommend adjuvant mitotane therapy for patients with stage III-IV ACC or any stage with a Ki-67 index >10%, who do not have macroscopic residual disease after surgery (18), this recommendation is based on low-quality evidence and expert opinions.